Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
Inflammatory Response01:28

Inflammatory Response

An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Inflammatory Bowel Disease I: Introduction01:26

Inflammatory Bowel Disease I: Introduction

Inflammatory bowel disease is a group of chronic disorders marked by recurrent inflammation of the gastrointestinal tract due to an abnormal immune response against gut microflora. This leads to tissue damage. The two main forms are Crohn’s disease and ulcerative colitis.Crohn’s DiseaseCrohn’s disease is a relapsing inflammatory disorder that can affect any part of the GI tract, from the mouth to the anus. It involves all layers of the bowel wall (transmural) and shows “skip lesions” in which...
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Vasoactive intestinal Peptide as a diagnostic or prognostic biomarker in multiple sclerosis: A systematic review.

Multiple sclerosis and related disorders·2026
Same author

Autologous and allogeneic haematopoietic cell transplantation in adult patients with Hodgkin lymphoma: recommendations from the EBMT Practice Harmonisation and Guidelines Committee and Lymphoma Working Party.

The Lancet. Haematology·2026
Same author

Endothelial cell damage in patients with acute graft versus host disease receiving treatment with extracorporeal photopheresis.

Frontiers in immunology·2026
Same author

Diagnostic value of HHV-6A/B genotyping in immunocompromised adults.

Journal of clinical microbiology·2026
Same author

Vasoactive intestinal peptide advances chondrogenesis and modulates pathogenic mediators in human osteoarthritis.

Journal of molecular medicine (Berlin, Germany)·2026
Same author

SCID newborn screening: seven-year performance and outcomes including T-cell lymphopenia in Catalonia (Spain).

Frontiers in immunology·2026

Related Experiment Video

Updated: Jul 9, 2026

Isolation and Th17 Differentiation of Naïve CD4 T Lymphocytes
12:59

Isolation and Th17 Differentiation of Naïve CD4 T Lymphocytes

Published on: September 26, 2013

Vasoactive intestinal peptide regulates Th17 function in autoimmune inflammation.

Javier Leceta1, Rosa P Gomariz, Carmen Martinez

  • 1Departamento de Biologia Celular, Facultad de Biologia, Universidad Complutense de Madrid, Madrid, Spain. jleceta@bio.ucm.es

Neuroimmunomodulation
|December 13, 2007
PubMed
Summary

Vasoactive intestinal peptide (VIP) modulates immune responses by targeting T helper 17 (Th17) and regulatory T (Treg) cells. This peptide shows potential as an immunomodulatory therapeutic agent for autoimmune diseases.

More Related Videos

In Vitro Differentiation of Naive CD4+ T Cells into Pathogenic Th17 Cells in Mouse
07:46

In Vitro Differentiation of Naive CD4+ T Cells into Pathogenic Th17 Cells in Mouse

Published on: October 25, 2024

Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice
08:37

Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice

Published on: April 21, 2015

Related Experiment Videos

Last Updated: Jul 9, 2026

Isolation and Th17 Differentiation of Naïve CD4 T Lymphocytes
12:59

Isolation and Th17 Differentiation of Naïve CD4 T Lymphocytes

Published on: September 26, 2013

In Vitro Differentiation of Naive CD4+ T Cells into Pathogenic Th17 Cells in Mouse
07:46

In Vitro Differentiation of Naive CD4+ T Cells into Pathogenic Th17 Cells in Mouse

Published on: October 25, 2024

Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice
08:37

Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice

Published on: April 21, 2015

Area of Science:

  • Immunology
  • Endocrinology
  • Autoimmune Diseases

Background:

  • Immune homeostasis relies on balancing pro-inflammatory and anti-inflammatory cytokines, including T helper 1 (Th1) and regulatory T (Treg) cells.
  • Autoimmune diseases arise from immune tolerance loss, often linked to cytokine and T cell imbalances.
  • Hormones and neuropeptides, like vasoactive intestinal peptide (VIP), are endogenous regulators of immune homeostasis with therapeutic potential.

Purpose of the Study:

  • To investigate the role of vasoactive intestinal peptide (VIP) in immune regulation.
  • To explore VIP's effects on T helper cell populations, particularly Th17 and Treg cells.
  • To evaluate VIP as a potential immunomodulatory therapeutic agent for autoimmune disorders.

Main Methods:

  • Review of existing literature on VIP, cytokines, and T cell subsets.
  • Analysis of studies investigating VIP's impact on inflammatory and anti-inflammatory immune responses.
  • Examination of VIP's influence on the Th17/Treg pathway in the context of autoimmune diseases.

Main Results:

  • VIP has demonstrated an ability to downregulate inflammatory responses.
  • VIP can shift the Th1/Th2 balance towards anti-inflammatory Th2 responses.
  • Emerging evidence highlights VIP's role in modulating the pathogenic Th17/Treg pathway.

Conclusions:

  • VIP acts as an immunomodulatory agent with therapeutic potential in autoimmune diseases.
  • VIP specifically targets the Th17/Treg pathway, offering a novel therapeutic strategy.
  • VIP's ability to balance immune responses makes it a promising candidate for managing autoimmune conditions.